CLINICAL_TRIALS ClinicalTrials.gov record with results posted

Phase III Multicenter Open-label Randomized Clinical Trial Comparing Everolimus and Low Dose Tacrolimus to Tacrolimus and Mycophenolate Mofetil at 6 mo Post-Transplant to Prevent Long-term Complications After Pediatric Heart Transplantation

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03386539
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-08-01T00:02:06.568074+00:00
Published At: 2026-07-31T00:00:00+00:00
Record Updated At: 2026-07-31
Results Posted At: 2026-07-31
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Pediatric Heart Transplantation", "Immunosuppression", "Chronic Kidney Diseases", "Cardiac Allograft Vasculopathy", "Heart Transplant Failure and Rejection", "Post-transplant Lymphoproliferative Disorder", "Heart Transplant Infection"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-07-31"
protocolSection.identificationModule.nctId: "NCT03386539"
protocolSection.identificationModule.officialTitle: "Phase III Multicenter Open-label Randomized Clinical Trial Comparing Everolimus and Low Dose Tacrolimus to Tacrolimus and Mycophenolate Mofetil at 6 mo Post-Transplant to Prevent Long-term Complications After Pediatric Heart Transplantation"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2026-07-31"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.